Share on StockTwits

Consort Medical plc (LON:CSRT)‘s stock had its “sell” rating reaffirmed by analysts at FinnCap in a research report issued to clients and investors on Thursday.

Shares of Consort Medical plc (LON:CSRT) traded up 3.99% during mid-day trading on Thursday, hitting GBX 951.5001. The stock had a trading volume of 8,514 shares. Consort Medical plc has a 52-week low of GBX 839.9999 and a 52-week high of GBX 1113.00. The stock has a 50-day moving average of GBX 918. and a 200-day moving average of GBX 931.. The company’s market cap is £274.5 million.

CSRT has been the subject of a number of other recent research reports. Analysts at Canaccord Genuity raised their price target on shares of Consort Medical plc from GBX 1,045 ($17.34) to GBX 1,182 ($19.62) in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Shore Capital upgraded shares of Consort Medical plc to a “buy” rating in a research note on Wednesday, July 2nd. Finally, analysts at Westhouse Securities reiterated a “buy” rating on shares of Consort Medical plc in a research note on Friday, June 20th. They now have a GBX 1,100 ($18.25) price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Consort Medical plc currently has an average rating of “Buy” and an average target price of GBX 1,019.22 ($16.91).

Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.